FDA clears Partner Therapeutics drug for bile duct cancer
The FDA approved Bizengri for adults with advanced bile duct cancer. In a study of 19 patients, nearly 37% saw tumor shrinkage using the new treatment.
Xurve View
Xurve View
The U.S. FDA approved Partner Therapeutics Bizengri for adults with rare advanced bile duct cancer on Friday. It is the first treatment approved for advanced cholangiocarcinoma patients carrying a specific genetic mutation after prior therapy failed. The approval marks the seventh use under the FDA's National Priority Voucher pilot program.
The FDA granted approval under a fast-track program designed to expedite reviews for rare diseases with limited options. Partner Therapeutics received the priority voucher on Wednesday, two days before the regulatory decision.
